BFM
BXRX

Boothbay Fund Management’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Boothbay Fund Management’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10
Closed -$10K – 2356
2021
Q2 		$10K Hold
10
– – ﹤0.01% 1805
2021
Q1 		$18K Hold
10
– – ﹤0.01% 1495
2020
Q4 		$14K Hold
10
– – ﹤0.01% 1204
2020
Q3 		$38K Hold
10
– – ﹤0.01% 1005
2020
Q2 		$57K Sell
10
-7
-41% -$33.6K ﹤0.01% 910
2020
Q1 		$60K Buy
+17
New +$161K 0.01% 775

Other funds holding BXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Boothbay Fund Management's BXRX Position: Q3 2021 in Review

Boothbay Fund Management sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q3 2021, closing a stake of 10 shares — an estimated $10K sold.

Boothbay Fund Management first reported a position in BXRX in Q1 2020 and held it in 6 quarters. The position peaked at $60K in Q1 2020. 26 funds tracked by Wall St. Rank hold BXRX as of Q3 2021.

  • Boothbay Fund Management reported no remaining Baudax Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Boothbay Fund Management sold 10 Baudax Bio, Inc. Common Stock shares in Q3 2021, an estimated $10K.
  • Boothbay Fund Management first reported a position in Baudax Bio, Inc. Common Stock in Q1 2020 and held it in 6 quarters.
  • Boothbay Fund Management's Baudax Bio, Inc. Common Stock position peaked at $60K in Q1 2020.
  • 26 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q3 2021.

Based on Boothbay Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.